6 O
ADVERSE O
REACTIONS O
EXCERPT O
: O
The O
most O
common O
reactions O
( O
> O
=3 O
% O
) O
were O
nausea O
, O
headache O
, O
diarrhea O
, O
insomnia O
, O
constipation O
and O
dizziness O
( O
6.2 O
) O
. O

To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Janssen O
Pharmaceuticals O
, O
Inc O
. O
at O
1-800-526-7736 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Serious O
and O
Otherwise O
Important O
Adverse O
Reactions O
The O
following O
serious O
and O
otherwise O
important O
adverse O
drug O
reactions O
are O
discussed O
in O
greater O
detail O
in O
other O
sections O
of O
labeling O
: O
* O
Disabling B-OSE_Labeled_AE
and I-OSE_Labeled_AE
Potentially I-OSE_Labeled_AE
Irreversible I-OSE_Labeled_AE
Serious I-OSE_Labeled_AE
Adverse I-OSE_Labeled_AE
Reactions I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
* O
Tendinitis B-OSE_Labeled_AE
and O
Tendon B-OSE_Labeled_AE
Rupture I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
* O
Peripheral B-OSE_Labeled_AE
Neuropathy I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
* O
Central B-OSE_Labeled_AE
Nervous I-OSE_Labeled_AE
System I-OSE_Labeled_AE
Effects I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
* O
Exacerbation B-OSE_Labeled_AE
of I-OSE_Labeled_AE
Myasthenia I-OSE_Labeled_AE
Gravis I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.5 O
) O
] O
* O
Other O
Serious O
and O
Sometimes O
Fatal B-NonOSE_AE
Reactions O
[ O
see O
Warnings O
and O
Precautions O
( O
5.6 O
) O
] O
* O
Hypersensitivity B-OSE_Labeled_AE
Reactions I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.7 O
) O
] O
* O
Hepatotoxicity B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.8 O
) O
] O
* O
Clostridium B-OSE_Labeled_AE
difficile I-OSE_Labeled_AE
- I-OSE_Labeled_AE
Associated I-OSE_Labeled_AE
Diarrhea I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.9 O
) O
] O
* O
Prolongation B-OSE_Labeled_AE
of I-OSE_Labeled_AE
the I-OSE_Labeled_AE
QT I-OSE_Labeled_AE
Interval I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.10 O
) O
] O
* O
Musculoskeletal B-OSE_Labeled_AE
Disorders I-OSE_Labeled_AE
in O
Pediatric O
Patients O
[ O
see O
Warnings O
and O
Precautions O
( O
5.11 O
) O
] O
* O
Blood B-OSE_Labeled_AE
Glucose I-OSE_Labeled_AE
Disturbances I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.12 O
) O
] O
* O
Photosensitivity B-OSE_Labeled_AE
/ O
Phototoxicity B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.13 O
) O
] O
* O
Development B-OSE_Labeled_AE
of I-OSE_Labeled_AE
Drug I-OSE_Labeled_AE
Resistant I-OSE_Labeled_AE
Bacteria I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.14 O
) O
] O
Hypotension O
has O
been O
associated O
with O
rapid O
or O
bolus O
intravenous O
infusion O
of O
LEVAQUIN O
( O
r O
) O
. O

LEVAQUIN O
( O
r O
) O
should O
be O
infused O
slowly O
over O
60 O
to O
90 O
minutes O
, O
depending O
on O
dosage O
[ O
see O
Dosage O
and O
Administration O
( O
2.5 O
) O
] O
. O

Crystalluria B-OSE_Labeled_AE
and O
cylindruria B-OSE_Labeled_AE
have O
been O
reported O
with O
quinolones O
, O
including O
LEVAQUIN O
( O
r O
) O
. O

Therefore O
, O
adequate O
hydration O
of O
patients O
receiving O
LEVAQUIN O
( O
r O
) O
should O
be O
maintained O
to O
prevent O
the O
formation B-NonOSE_AE
of I-NonOSE_AE
a I-NonOSE_AE
highly I-NonOSE_AE
concentrated I-NonOSE_AE
urine I-NonOSE_AE
[ O
see O
Dosage O
and O
Administration O
( O
2.5 O
) O
] O
. O

6.2 O
Clinical O
Trial O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

The O
data O
described O
below O
reflect O
exposure O
to O
LEVAQUIN O
( O
r O
) O
in O
7537 O
patients O
in O
29 O
pooled O
Phase O
3 O
clinical O
trials O
. O

The O
population O
studied O
had O
a O
mean O
age O
of O
50 O
years O
( O
approximately O
74 O
% O
of O
the O
population O
was O
< O
65 O
years O
of O
age O
) O
, O
50 O
% O
were O
male O
, O
71 O
% O
were O
Caucasian O
, O
19 O
% O
were O
Black O
. O

Patients O
were O
treated O
with O
LEVAQUIN O
( O
r O
) O
for O
a O
wide O
variety O
of O
infectious O
diseases O
[ O
see O
Indications O
and O
Usage O
( O
1 O
) O
] O
. O

Patients O
received O
LEVAQUIN O
( O
r O
) O
doses O
of O
750 O
mg O
once O
daily O
, O
250 O
mg O
once O
daily O
, O
or O
500 O
mg O
once O
or O
twice O
daily O
. O

Treatment O
duration O
was O
usually O
3-14 O
days O
, O
and O
the O
mean O
number O
of O
days O
on O
therapy O
was O
10 O
days O
. O

The O
overall O
incidence O
, O
type O
and O
distribution O
of O
adverse O
reactions O
was O
similar O
in O
patients O
receiving O
LEVAQUIN O
( O
r O
) O
doses O
of O
750 O
mg O
once O
daily O
, O
250 O
mg O
once O
daily O
, O
and O
500 O
mg O
once O
or O
twice O
daily O
. O

Discontinuation O
of O
LEVAQUIN O
( O
r O
) O
due O
to O
adverse O
drug O
reactions O
occurred O
in O
4.3 O
% O
of O
patients O
overall O
, O
3.8 O
% O
of O
patients O
treated O
with O
the O
250 O
mg O
and O
500 O
mg O
doses O
and O
5.4 O
% O
of O
patients O
treated O
with O
the O
750 O
mg O
dose O
. O

The O
most O
common O
adverse O
drug O
reactions O
leading O
to O
discontinuation O
with O
the O
250 O
and O
500 O
mg O
doses O
were O
gastrointestinal O
( O
1.4 O
% O
) O
, O
primarily O
nausea B-OSE_Labeled_AE
( O
0.6 O
% O
) O
; O
vomiting B-OSE_Labeled_AE
( O
0.4 O
% O
) O
; O
dizziness B-OSE_Labeled_AE
( O
0.3 O
% O
) O
; O
and O
headache B-OSE_Labeled_AE
( O
0.2 O
% O
) O
. O

The O
most O
common O
adverse O
drug O
reactions O
leading O
to O
discontinuation O
with O
the O
750 O
mg O
dose O
were O
gastrointestinal O
( O
1.2 O
% O
) O
, O
primarily O
nausea B-OSE_Labeled_AE
( O
0.6 O
% O
) O
, O
vomiting B-OSE_Labeled_AE
( O
0.5 O
% O
) O
; O
dizziness B-OSE_Labeled_AE
( O
0.3 O
% O
) O
; O
and O
headache B-OSE_Labeled_AE
( O
0.3 O
% O
) O
. O

Adverse O
reactions O
occurring O
in O
> O
=1 O
% O
of O
LEVAQUIN O
( O
r O
) O
-treated O
patients O
and O
less O
common O
adverse O
reactions O
, O
occurring O
in O
0.1 O
to O
< O
1 O
% O
of O
LEVAQUIN O
( O
r O
) O
-treated O
patients O
, O
are O
shown O
in O
Table O
4 O
and O
Table O
5 O
, O
respectively O
. O

The O
most O
common O
adverse O
drug O
reactions O
( O
> O
=3 O
% O
) O
are O
nausea B-OSE_Labeled_AE
, O
headache B-OSE_Labeled_AE
, O
diarrhea B-OSE_Labeled_AE
, O
insomnia B-OSE_Labeled_AE
, O
constipation B-OSE_Labeled_AE
, O
and O
dizziness B-OSE_Labeled_AE
. O

Table O
4 O
: O
Common O
( O
> O
=1 O
% O
) O
Adverse O
Reactions O
Reported O
in O
Clinical O
Trials O
with O
LEVAQUIN O
( O
r O
) O
System/Organ O
Class O
Adverse O
Reaction O
% O
( O
N O
= O
7537 O
) O
Infections B-NonOSE_AE
and I-NonOSE_AE
Infestations I-NonOSE_AE
moniliasis B-OSE_Labeled_AE
1 O
Psychiatric B-NonOSE_AE
Disorders I-NonOSE_AE
insomnia B-OSE_Labeled_AE
[ O
note O
: O
N O
= O
7274 O
] O
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
4 O
Nervous B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
headache B-OSE_Labeled_AE
dizziness O
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
63 O
Respiratory B-NonOSE_AE
, I-NonOSE_AE
Thoracic I-NonOSE_AE
and I-NonOSE_AE
Mediastinal I-NonOSE_AE
Disorders I-NonOSE_AE
dyspnea B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.7 O
) O
] O
1 O
Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
nausea B-OSE_Labeled_AE
7 O
diarrhea B-OSE_Labeled_AE
5 O
constipation B-OSE_Labeled_AE
3 O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
2 O
vomiting B-OSE_Labeled_AE
2 O
dyspepsia B-OSE_Labeled_AE
2 O
Skin B-NonOSE_AE
and I-NonOSE_AE
Subcutaneous I-NonOSE_AE
Tissue I-NonOSE_AE
Disorders I-NonOSE_AE
rash B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.7 O
) O
] O
pruritus B-OSE_Labeled_AE
21 O
Reproductive B-NonOSE_AE
System I-NonOSE_AE
and I-NonOSE_AE
Breast I-NonOSE_AE
Disorders I-NonOSE_AE
vaginitis B-OSE_Labeled_AE
1 O
[ O
note O
: O
N O
= O
3758 O
( O
women O
) O
] O
General B-NonOSE_AE
Disorders I-NonOSE_AE
and I-NonOSE_AE
Administration I-NonOSE_AE
Site I-NonOSE_AE
Conditions I-NonOSE_AE
edema B-OSE_Labeled_AE
1 O
injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
1 O
chest B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
1 O
Table O
5 O
: O
Less O
Common O
( O
0.1 O
to O
1 O
% O
) O
Adverse O
Reactions O
Reported O
in O
Clinical O
Trials O
with O
LEVAQUIN O
( O
r O
) O
( O
N O
= O
7537 O
) O
System/Organ O
Class O
Adverse O
Reaction O
Infections B-NonOSE_AE
and I-NonOSE_AE
Infestations I-NonOSE_AE
genital B-OSE_Labeled_AE
moniliasis I-OSE_Labeled_AE
Blood B-NonOSE_AE
and I-NonOSE_AE
Lymphatic I-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
anemia B-OSE_Labeled_AE
thrombocytopeniagranulocytopenia O
[ O
see O
Warnings O
and O
Precautions O
( O
5.6 O
) O
] O
Immune B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
allergic B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.6 O
, O
5.7 O
) O
] O
Metabolism B-NonOSE_AE
and I-NonOSE_AE
Nutrition I-NonOSE_AE
Disorders I-NonOSE_AE
hyperglycemia B-OSE_Labeled_AE
hypoglycemia O
[ O
see O
Warnings O
and O
Precautions O
( O
5.12 O
) O
] O
hyperkalemia B-OSE_Labeled_AE
Psychiatric B-NonOSE_AE
Disorders I-NonOSE_AE
anxiety B-OSE_Labeled_AE
agitationconfusiondepressionhallucinationnightmare O
[ O
note O
: O
N O
= O
7274 O
] O
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
sleep B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
anorexiaabnormal O
dreaming O
Nervous B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
tremor B-OSE_Labeled_AE
convulsions O
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
paresthesia B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
vertigo B-OSE_Labeled_AE
hypertoniahyperkinesiasabnormal O
gaitsomnolencesyncope O
Respiratory B-NonOSE_AE
, I-NonOSE_AE
Thoracic I-NonOSE_AE
and I-NonOSE_AE
Mediastinal I-NonOSE_AE
Disorders I-NonOSE_AE
epistaxis B-OSE_Labeled_AE
Cardiac B-NonOSE_AE
Disorders I-NonOSE_AE
cardiac B-OSE_Labeled_AE
arrest I-OSE_Labeled_AE
palpitationventricular O
tachycardiaventricular O
arrhythmia O
Vascular B-NonOSE_AE
Disorders I-NonOSE_AE
phlebitis B-OSE_Labeled_AE
Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
gastritis B-OSE_Labeled_AE
stomatitispancreatitisesophagitisgastroenteritisglossitispseudomembranous/ O
C B-OSE_Labeled_AE
. I-OSE_Labeled_AE
difficile I-OSE_Labeled_AE
colitis I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.9 O
) O
] O
Hepatobiliary B-NonOSE_AE
Disorders I-NonOSE_AE
abnormal B-OSE_Labeled_AE
hepatic I-OSE_Labeled_AE
function I-OSE_Labeled_AE
increased O
hepatic O
enzymesincreased O
alkaline O
phosphatase O
Skin B-NonOSE_AE
and I-NonOSE_AE
Subcutaneous I-NonOSE_AE
Tissue I-NonOSE_AE
Disorders I-NonOSE_AE
urticaria B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.7 O
) O
] O
Musculoskeletal B-NonOSE_AE
and I-NonOSE_AE
Connective I-NonOSE_AE
Tissue I-NonOSE_AE
Disorders I-NonOSE_AE
arthralgia B-OSE_Labeled_AE
tendinitis O
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
myalgia B-OSE_Labeled_AE
skeletal O
pain O
Renal B-NonOSE_AE
and I-NonOSE_AE
Urinary I-NonOSE_AE
Disorders I-NonOSE_AE
abnormal B-OSE_Labeled_AE
renal I-OSE_Labeled_AE
function I-OSE_Labeled_AE
acute O
renal O
failure O
[ O
see O
Warnings O
and O
Precautions O
( O
5.6 O
) O
] O
In O
clinical O
trials O
using O
multiple-dose O
therapy O
, O
ophthalmologic B-OSE_Labeled_AE
abnormalities I-OSE_Labeled_AE
, O
including O
cataracts B-OSE_Labeled_AE
and O
multiple B-OSE_Labeled_AE
punctate I-OSE_Labeled_AE
lenticular I-OSE_Labeled_AE
opacities I-OSE_Labeled_AE
, O
have O
been O
noted O
in O
patients O
undergoing O
treatment O
with O
quinolones O
, O
including O
LEVAQUIN O
( O
r O
) O
. O

The O
relationship O
of O
the O
drugs O
to O
these O
events O
is O
not O
presently O
established O
. O

6.3 O
Postmarketing O
Experience O
Table O
6 O
lists O
adverse O
reactions O
that O
have O
been O
identified O
during O
post-approval O
use O
of O
LEVAQUIN O
( O
r O
) O
. O

Because O
these O
reactions O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
not O
always O
possible O
to O
reliably O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
. O

Table O
6 O
: O
Postmarketing O
Reports O
Of O
Adverse O
Drug O
Reactions O
System/Organ O
Class O
Adverse O
Reaction O
Blood B-NonOSE_AE
and I-NonOSE_AE
Lymphatic I-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
pancytopenia B-OSE_Labeled_AE
aplastic O
anemialeukopeniahemolytic O
anemia O
[ O
see O
Warnings O
and O
Precautions O
( O
5.6 O
) O
] O
eosinophilia B-OSE_Labeled_AE
Immune B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
hypersensitivity B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
, O
sometimes O
fatal B-NonOSE_AE
including O
: O
anaphylactic B-OSE_Labeled_AE
/anaphylactoid O
reactions I-OSE_Labeled_AE
anaphylactic B-OSE_Labeled_AE
shock I-OSE_Labeled_AE
angioneurotic B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
serum B-OSE_Labeled_AE
sickness I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.6 O
, O
5.7 O
) O
] O
Psychiatric B-NonOSE_AE
Disorders I-NonOSE_AE
psychosis B-OSE_Labeled_AE
paranoiaisolated O
reports O
of O
suicidal B-OSE_Labeled_AE
ideation I-OSE_Labeled_AE
, O
suicide B-OSE_Labeled_AE
attempt I-OSE_Labeled_AE
and O
completed B-OSE_Labeled_AE
suicide I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
Nervous B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
exacerbation B-OSE_Labeled_AE
of I-OSE_Labeled_AE
myasthenia I-OSE_Labeled_AE
gravis I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.5 O
) O
] O
anosmia B-OSE_Labeled_AE
ageusiaparosmiadysgeusiaperipheral O
neuropathy O
( O
may O
be O
irreversible O
) O
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
isolated O
reports O
of O
encephalopathy B-OSE_Labeled_AE
abnormal O
electroencephalogram O
( O
EEG O
) O
dysphonia B-OSE_Labeled_AE
pseudotumor O
cerebri O
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
Eye B-NonOSE_AE
Disorders I-NonOSE_AE
uveitis B-OSE_Labeled_AE
vision O
disturbance O
, O
including O
diplopia B-OSE_Labeled_AE
visual O
acuity B-OSE_Labeled_AE
reduced I-OSE_Labeled_AE
vision O
blurredscotoma O
Ear B-NonOSE_AE
and I-NonOSE_AE
Labyrinth I-NonOSE_AE
Disorders I-NonOSE_AE
hypoacusis B-OSE_Labeled_AE
tinnitus O
Cardiac B-NonOSE_AE
Disorders I-NonOSE_AE
isolated O
reports O
of O
torsade B-OSE_Labeled_AE
de I-OSE_Labeled_AE
pointes I-OSE_Labeled_AE
electrocardiogram O
QT O
prolonged O
[ O
see O
Warnings O
and O
Precautions O
( O
5.10 O
) O
] O
tachycardia B-OSE_Labeled_AE
Vascular B-NonOSE_AE
Disorders I-NonOSE_AE
vasodilatation B-OSE_Labeled_AE
Respiratory B-NonOSE_AE
, I-NonOSE_AE
Thoracic I-NonOSE_AE
and I-NonOSE_AE
Mediastinal I-NonOSE_AE
Disorders I-NonOSE_AE
isolated O
reports O
of O
allergic B-OSE_Labeled_AE
pneumonitis I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.6 O
) O
] O
Hepatobiliary B-NonOSE_AE
Disorders I-NonOSE_AE
hepatic B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
( O
including O
fatal B-NonOSE_AE
cases O
) O
hepatitis B-OSE_Labeled_AE
jaundice O
[ O
see O
Warnings O
and O
Precautions O
( O
5.6 O
) O
, O
( O
5.8 O
) O
] O
Skin B-NonOSE_AE
and I-NonOSE_AE
Subcutaneous I-NonOSE_AE
Tissue I-NonOSE_AE
Disorders I-NonOSE_AE
bullous B-OSE_Labeled_AE
eruptions I-OSE_Labeled_AE
to O
include O
: O
Stevens B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Johnson I-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
toxic B-OSE_Labeled_AE
epidermal I-OSE_Labeled_AE
necrolysis I-OSE_Labeled_AE
Acute O
Generalized O
Exanthematous O
Pustulosis O
( O
AGEP O
) O
fixed B-OSE_Labeled_AE
drug I-OSE_Labeled_AE
eruptions I-OSE_Labeled_AE
erythema B-OSE_Labeled_AE
multiforme I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.6 O
) O
] O
photosensitivity B-OSE_Labeled_AE
/ O
phototoxicity B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.13 O
) O
] O
leukocytoclastic B-OSE_Labeled_AE
vasculitis I-OSE_Labeled_AE
Musculoskeletal B-NonOSE_AE
and I-NonOSE_AE
Connective I-NonOSE_AE
Tissue I-NonOSE_AE
Disorders I-NonOSE_AE
tendon B-OSE_Labeled_AE
rupture I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
muscle B-OSE_Labeled_AE
injury I-OSE_Labeled_AE
, O
including O
rupture O
rhabdomyolysis B-OSE_Labeled_AE
Renal B-NonOSE_AE
and I-NonOSE_AE
Urinary I-NonOSE_AE
Disorders I-NonOSE_AE
interstitial B-OSE_Labeled_AE
nephritis I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.6 O
) O
] O
General B-NonOSE_AE
Disorders I-NonOSE_AE
and I-NonOSE_AE
Administration I-NonOSE_AE
Site I-NonOSE_AE
Conditions I-NonOSE_AE
multi B-OSE_Labeled_AE
- I-OSE_Labeled_AE
organ I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
pyrexia O
Investigations B-NonOSE_AE
prothrombin B-OSE_Labeled_AE
time I-OSE_Labeled_AE
prolonged I-OSE_Labeled_AE
international O
normalized O
ratio O
prolongedmuscle O
enzymes O
increased O

